Thus, CCL5 was identified as an associated mediator of drug resistance to tamoxifen, saracatinib, and chemotherapeutics in breast cancer and several chemotherapeutics like doxorubicin, cisplatin, or taxanes were shown to upregulate the CCL5‐CCR1/CCR5 pathway in human melanoma cell lines or prostate cancer cells (Fang et al., 2018; Ullah et al., 2019; Yi et al., 2013). This evidence concerns the gene CCL5 and prostate carcinoma.